Name: DENALI THERAPEUTICS INC (DNLI) Stock
Brand: DENALI THERAPEUTICS INC
Rating: 5.5 (3 reviews)

DNLI Latest News, Press Relases and Analysis

All

Press Releases

14 days ago - By: Zacks Investment Research - Mentions: BIIB ALKS TAK

DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug

15 days ago - By: Denali Therapeutics Inc.

Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

15 days ago - By: Denali Therapeutics Inc.

Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

15 days ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces Board and Executive Leadership Updates

15 days ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces Board and Executive Leadership Updates

a month ago - By: Benzinga

FDA Delays Decision Date For Denali Therapeutics' Lead Drug Candidate

a month ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)

a month ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)

2 months ago - By: Zacks Investment Research - Mentions: MNKD

Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report?

3 months ago - By: Zacks Investment Research - Mentions: BIIB CRMD

DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26

10 months ago - By: Benzinga - Mentions: JPM

Why Is Denali Therapeutics Stock Trading Higher On Wednesday?

3 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

3 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

4 months ago - By: Zacks Investment Research - Mentions: CPRX ACAD

Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?

4 months ago - By: Yahoo Finance

Denali Therapeutics Inc. (DNLI) Secures FDA Priority Review for First-Ever Brain-Penetrant Hunter Syndrome Therapy

4 months ago - By: Yahoo Finance

BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target

5 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)

6 months ago - By: Zacks Investment Research - Mentions: MRNA

Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report?

7 months ago - By: Zacks Investment Research - Mentions: SNY BIIB

Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus

7 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

7 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

8 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

8 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

9 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

9 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

10 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

10 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

10 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™

10 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

11 months ago - By: Denali Therapeutics Inc.

Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

11 months ago - By: Denali Therapeutics Inc.

DENALI THERAPEUTICS INC (DNLI) Stock News

DNLI Latest News, Press Relases and Analysis